Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable or Metastatic Colorectal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04017650
What this trial is testing

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Who this might be right for
BRAF NP_004324.2:p.V600EMetastatic Colon AdenocarcinomaMetastatic Microsatellite Stable Colorectal Carcinoma+13 more
M.D. Anderson Cancer Center 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07623642
What this trial is testing

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Who this might be right for
Uterine Cervical NeoplasmsTriple Negative Breast NeoplasmsProstatic Neoplasms+8 more
GV20 Therapeutics 227
Testing effectiveness (Phase 2)Study completedNCT00778102
What this trial is testing

Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.

Who this might be right for
Colorectal Cancer
Hoffmann-La Roche 80
Testing effectiveness (Phase 2)Looking for participantsNCT05706129
What this trial is testing

Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Clear Cell Renal Cell Cancer (ccRCC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+6 more
Lumara Bio Oncologics GmbH 270
Testing effectiveness (Phase 2)Study completedNCT00077337
What this trial is testing

FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
SWOG Cancer Research Network
Testing effectiveness (Phase 2)Study completedNCT01328171
What this trial is testing

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

Who this might be right for
Metastatic Colorectal Cancer
AIO-Studien-gGmbH 93
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Early research (Phase 1)Study completedNCT01437007
What this trial is testing

TKM 080301 for Primary or Secondary Liver Cancer

Who this might be right for
Colorectal Cancer With Hepatic MetastasesPancreas Cancer With Hepatic MetastaseGastric Cancer With Hepatic Metastase+2 more
National Cancer Institute (NCI) 1
Early research (Phase 1)Looking for participantsNCT07589205
What this trial is testing

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Who this might be right for
Solid TumorColorectal CancerNon-small Cell Lung Cancer+2 more
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 493
Early research (Phase 1)Study completedNCT00031681
What this trial is testing

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Who this might be right for
Advanced Adult Primary Liver CancerCarcinoma of the AppendixEstrogen Receptor-negative Breast Cancer+85 more
National Cancer Institute (NCI) 41